Moderna (MRNA) set to cure COVID-19 – is now the time to invest?

MRNA’s key COVID-19 developments so far

  • US government is willing to fund mRNA-173 through every trial until regulatory approval.
  • Biomedical Advanced Research and Development Authority (BARDA) is ready to give Moderna (NASDAQ: MRNA) $483 million to expedite mRNA-173 through clinical development.
  • Lonza Group, via its agreement with Moderna, is manufacturing mRNA-173 at their US and Switzerland operations.
Read more

Hoth Therapeutics gaining ground in the race for a COVID-19 vaccine

In recent weeks, Biotech companies across the globe have been collaborating together to produce a COVID-19 vaccine for global production and distribution. The reward for such an accomplishment would add prestige and intrinsic value at a scale we have never witnessed. The vaccine will save millions of lives in the years to follow, as well as give biopharmas insight into preventing future strands of the Coronavirus.… Read more